Monoclonal antibody-based immunologics R&D firm will take a $2 mil.-$3 mil. one time charge to earnings related to expenses incurred with planned unification and expansion of operations in the La Jolla/San Diego area, IDEC said Feb. 12. The company explained it has outgrown its Mountain View, Calif. facilities near San Francisco and needs to scale up for future production of commercialized products. The new site is expected to be completed by the end of 1993. Separately, VP-Medical Research and company director Richard Miller, MD, has resigned to "take an active role" at Pharmacyclics, Inc., a start-up he cofounded. Pharmacyclics is "focused on technology involving synthetic chemical agents for medical applications," IDEC said....
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth